Magnesium Sulfate in Children Undergoing Laparoscopic Appendectomy

Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18-18
SponsorMedical University of Warsaw

About this trial

Magnesium sulfate is one of the most commonly used co-analgetics. Its antinociceptive effect is related to antagonizing NMDA (N-methyl-D-aspartate) receptors of the nervous system, has an anti-inflammatory effect by reducing the concentration of IL-6 (interleukin 6) and tumor necrosis factor alpha. In adult patients, the need for morphine in the perioperative period is reduced when magnesium infusion is used. In current guidelines for treatment of acute pain in children, magnesium sulfate may be considered as a co-analgetic. However, the strength of such a recommendation is low due to the lack of reliable scientific research confirming the effectiveness of magnesium infusion in the pediatric population. The aim of this study is to evaluate the efficacy of intravenous magnesium sulfate infusion on the opioid consumption, the circulatory, metabolic and hormonal response to intubation and surgical trauma during anesthesia for laparoscopic appendectomy in children.

Eligibility criteria

Qualifiers

ASA (American Society of Anesthesiologists) physical status class 1E, 2E, 3E (E - emergency)

Patients undergoing laparoscopic appendectomy

Disqualifiers

Allergy to the magnesium sulfate or the excipient

Hypermagnesemia

Renal failure (GFR <30 ml/min)

Myasthenia gravis

Trial design

Treatments tested in this trial

  • Intravenous magnesium sulfate
  • Normal saline infusion

Treatment groups

188 Participants
are divided into 2 treatment groups

Sponsors and collaborators